Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation

International Journal of Cancer

Volumn 129, Issue 4, 2011, Pages 903-909

  Heymans, Julie ^a   Benoy, Ina H ^b   Poppe, Willy ^a   Depuydt, Christophe E ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Laboratory for Clinical Pathology   (Belgium)

Author keywords

CIN; conisation; real time PCR; recurrence; viral load

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER GRADING; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADULT; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; CONIZATION; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 79959755250     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25745     Document Type: Article

References (33)

1. Franco EL, Rohan TE, Villa LL,. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999; 91: 506-11. (Pubitemid 29157058)
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N,. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19. (Pubitemid 29406813)
3. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ,. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325 (7364): 572-8.
4. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV,. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65. (Pubitemid 34293391)
5. Holowaty P, Miller AB, Rohan T, To T,. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999; 91: 252-8. (Pubitemid 29090994)
6. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J,. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24 (Suppl 3): 78-89.
7. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, Voorhorst FJ, van Kemenade FJ, Rozendaal L, Meijer CJ,. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analyis. Obstet Gynecol Surv 2004; 59: 543-53. (Pubitemid 38802827)
8. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ,. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354: 20-5. (Pubitemid 29304297)
9. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J,. Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN. An update of pooled evidence. Gynecol Oncol 2005; 99 (Suppl 3): 7-11.
10. Chew GK, Jandial L, Paraskevaidis E, Kitchener HC,. Pattern of CIN recurrence following laser ablation treatment: long-term follow-up. Int J Gynecol Cancer 1999; 9: 487-90. (Pubitemid 30027553)
11. Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen, Poppe W,. Prediction of recurrence after treatment for high-grade cervical intraepihelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG 2006; 113: 1303-7. (Pubitemid 44581521)
12. Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Campo E, Pahisa J, Ordi J,. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006; 103: 631-6. (Pubitemid 44602179)
13. Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, Makrydimas G, Tofoski J, Roukos DH,. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004; 30: 205-11; Review. (Pubitemid 38418058)
14. Brismar S, Johansson B, Borjesson M, Arbyn M, Andersson S,. Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. Am J Obstet Gynecol 2009; 201: 17.e1-8.
15. Zielinski GD, Rozendaal L, Voorhorst FJ, Berkhof J, Snijders P, Risse E, Runsink AP, de Schipper FA, Meijer CJ,. HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3. Gynaecol Oncol 2003; 91: 67-73. (Pubitemid 37188595)
16. Chua K-L, Hjerpe A,. Human papillomavirus analysis as a prognostic marker following conisation of the cervix uteri. Gynecol Oncol 1997; 66: 108-13. (Pubitemid 27329317)
17. Jordan J, Martin-Hirsch P, Arbyn M, Schenck U, Baldauf JJ, Da Silva D, Anttila A, Nieminen P, Prendiville W,. European guidelines for clinical management of abnormal cervical cytology, part 2. Cytopathology 2009; 20: 5-16.
18. Arbyn M, Herbert A, Schenck U, Nieminen P, Jordan J, McGoogan E, Patnick J, Bergeron C, Baldauf JJ, Klinkhamer P, Bulten J, Martin-Hirsch P,. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007; 18: 133-9. (Pubitemid 46934510)
19. Vassilakos P, Saurel J, Rondez R,. Direct-to-vial use of the AutoCyte PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories. Acta Cytol 1999; 43: 65-8. (Pubitemid 29071878)
20. Vassilakos P, Griffin S, Megevand E, Campana A,. CytoRich liquid-based cervical cytologic test. Screening results in a routine cytopathology service. Acta Cytol 1998; 42: 198-202.
21. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Jr, Young N,; Forum Group Members; Bethesda, 2001 Workshop. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-19. (Pubitemid 34437346)
22. Herbert A, Bergeron C, Wiener H, Schenck U, Klinkhamer PJ, Bulten J, Arbyn M,. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology 2007; 18: 213-19. (Pubitemid 47076369)
23. Depuydt C, Vereecken AJ, Salembier GM, Vanbrabant AS, Boels LA, van Herck E, Arbyn M, Segers K, Bogers JJ,. Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. Br J Cancer 2003; 88: 560-6. (Pubitemid 36363365)
24. Depuydt C, Benoy IH, Bailleul EJ, Vandepitte J, Vereecken AJ, Bogers JJ,. Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi. Cytopathology 2006; 17: 374-81. (Pubitemid 44808532)
25. Depuydt CE, Boulet GA, Horvath CA, Benoy IH, Vereecken AJ, Bogers JJ,. Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med 2007; 11: 881-91. (Pubitemid 47313308)
26. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ,; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27. (Pubitemid 36159887)
27. Schoonjans F, Zalata A, Depuydt CE, Comhaire FH,. MedCalc: a new computer program for medical statistics. Comput Methods Programs Biomed 1995; 48: 257-62. (Pubitemid 26020881)
28. Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, Wheeler CM, Castle PE,. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 2006; 15: 908-14. (Pubitemid 43823517)
29. Bollen Liesbeth JM, Tjong-A-Hung, Steven P, van der Velden Jacobus, Mol Ben-Willem, ten Kate Fiebo WJ, ter Schegget Jan-Bleker, Otto P,. Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecol Oncol 1999; 72: 199-201. (Pubitemid 29093775)
30. Nagai Y, Maehama T, Asato T, Kanazawa K,. Persistence of human papillomavirus infection after therapeutic conisation for CIN 3: is it an alarm for disease recurrence? Gynecol Oncol 2000; 79: 294-9.
31. Soutter WP, de Barros Lopes A, Fletcher A, Monaghan JM, Duncan ID, Paraskevaidis E, Kitchener HC,. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997; 349: 978-80. (Pubitemid 27149800)
32. Nobbenhuis MAE, Meijer CJLM, Brule AJC, van den Rozendaal L, Voorhorst FJ, Risse EKJ, Verheijen RHM, Helmerhorst TJM,. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001; 84: 769-801.
33. Gök M, Coupé VMH, Berkhof J, Verheijen RHM, Helmerhorst TJM, Hogewoning CJA, Snijders PJF, Meijer CJLM,. HPV16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol 2007; 104: 273-5. (Pubitemid 46135672)